152 related articles for article (PubMed ID: 28963790)
1. Phase I study of induction chemotherapy with afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA/IVB human papillomavirus-associated oropharyngeal squamous cell cancer.
Dunn LA; Fury MG; Sherman EJ; Ho AA; Katabi N; Haque SS; Pfister DG
Head Neck; 2018 Feb; 40(2):233-241. PubMed ID: 28963790
[TBL] [Abstract][Full Text] [Related]
2. Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study.
Chen AM; Felix C; Wang PC; Hsu S; Basehart V; Garst J; Beron P; Wong D; Rosove MH; Rao S; Melanson H; Kim E; Palmer D; Qi L; Kelly K; Steinberg ML; Kupelian PA; Daly ME
Lancet Oncol; 2017 Jun; 18(6):803-811. PubMed ID: 28434660
[TBL] [Abstract][Full Text] [Related]
3. A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma.
Chung CH; Rudek MA; Kang H; Marur S; John P; Tsottles N; Bonerigo S; Veasey A; Kiess A; Quon H; Cmelak A; Murphy BA; Gilbert J
Oral Oncol; 2016 Feb; 53():54-9. PubMed ID: 26705063
[TBL] [Abstract][Full Text] [Related]
4. A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors.
O'Brien MER; Sarker D; Bhosle J; Thillai K; Yap TA; Uttenreuther-Fischer M; Pemberton K; Jin X; Wiebe S; de Bono J; Spicer J
Cancer Chemother Pharmacol; 2018 Nov; 82(5):757-766. PubMed ID: 30088048
[TBL] [Abstract][Full Text] [Related]
5. Weekly paclitaxel and carboplatin combination chemotherapy in patients with advanced squamous cell carcinoma of the head and neck.
Moosmann P; Egli F; Stahel RA; Jost L
Onkologie; 2003 Dec; 26(6):568-72. PubMed ID: 14709932
[TBL] [Abstract][Full Text] [Related]
6. OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.
Seiwert TY; Foster CC; Blair EA; Karrison TG; Agrawal N; Melotek JM; Portugal L; Brisson RJ; Dekker A; Kochanny S; Gooi Z; Lingen MW; Villaflor VM; Ginat DT; Haraf DJ; Vokes EE
Ann Oncol; 2019 Feb; 30(2):297-302. PubMed ID: 30481287
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx.
Loong HH; Winquist E; Waldron J; Chen EX; Kim J; Palma D; Read N; Razak AR; Diaz-Padilla I; Chan K; Bayley A; Hossain M; Wang L; Chin S; Siu LL; Hope A
Eur J Cancer; 2014 Sep; 50(13):2263-70. PubMed ID: 24953566
[TBL] [Abstract][Full Text] [Related]
8. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number.
Worden FP; Kumar B; Lee JS; Wolf GT; Cordell KG; Taylor JM; Urba SG; Eisbruch A; Teknos TN; Chepeha DB; Prince ME; Tsien CI; D'Silva NJ; Yang K; Kurnit DM; Mason HL; Miller TH; Wallace NE; Bradford CR; Carey TE
J Clin Oncol; 2008 Jul; 26(19):3138-46. PubMed ID: 18474879
[TBL] [Abstract][Full Text] [Related]
9. Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment.
Rosenberg AJ; Izumchenko E; Pearson A; Gooi Z; Blair E; Karrison T; Juloori A; Ginat D; Cipriani N; Lingen M; Sloane H; Edelstein DL; Keyser K; Fredebohm J; Holtrup F; Jones FS; Haraf D; Agrawal N; Vokes EE
BMC Cancer; 2022 Jan; 22(1):17. PubMed ID: 34980038
[TBL] [Abstract][Full Text] [Related]
10. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.
Fakhry C; Westra WH; Li S; Cmelak A; Ridge JA; Pinto H; Forastiere A; Gillison ML
J Natl Cancer Inst; 2008 Feb; 100(4):261-9. PubMed ID: 18270337
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
Abaid LN; Micha JP; Rettenmaier MA; Brown JV; Mendivil AA; Lopez KL; Goldstein BH
Cancer Chemother Pharmacol; 2013 Jul; 72(1):101-7. PubMed ID: 23660691
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck.
Shin DM; Glisson BS; Khuri FR; Lippman SM; Ginsberg L; Diaz E; Papadimitrakopoulou V; Feng L; Francisco M; Garden A; Kies MS; Myers J; Clayman G; Hong WK
Cancer; 2002 Jul; 95(2):322-30. PubMed ID: 12124833
[TBL] [Abstract][Full Text] [Related]
13. Weekly chemotherapy with radiation versus high-dose cisplatin with radiation as organ preservation for patients with HPV-positive and HPV-negative locally advanced squamous cell carcinoma of the oropharynx.
Dobrosotskaya IY; Bellile E; Spector ME; Kumar B; Feng F; Eisbruch A; Wolf GT; Prince ME; Moyer JS; Teknos T; Chepeha DB; Walline HM; McHugh JB; Cordell KG; Ward PD; Byrd S; Maxwell JH; Urba S; Bradford CR; Carey TE; Worden FP
Head Neck; 2014 May; 36(5):617-23. PubMed ID: 23596055
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
[TBL] [Abstract][Full Text] [Related]
15. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study).
Choy H; Devore RF; Hande KR; Porter LL; Rosenblatt P; Yunus F; Schlabach L; Smith C; Shyr Y; Johnson DH
Int J Radiat Oncol Biol Phys; 2000 Jul; 47(4):931-7. PubMed ID: 10863062
[TBL] [Abstract][Full Text] [Related]
17. An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.
Spigel DR; Luft A; Depenbrock H; Ramlau R; Khalil M; Kim JH; Mayo C; Chao GY; Obasaju C; Natale R
Clin Lung Cancer; 2017 Sep; 18(5):480-488. PubMed ID: 28365238
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
Choong NW; Vokes EE; Haraf DJ; Tothy PK; Ferguson MK; Kasza K; Rudin CM; Hoffman PC; Krauss SA; Szeto L; Mauer AM
J Thorac Oncol; 2008 Jan; 3(1):59-67. PubMed ID: 18166842
[TBL] [Abstract][Full Text] [Related]
19. A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma.
Czito BG; Kelsey CR; Hurwitz HI; Willett CG; Morse MA; Blobe GC; Fernando NH; D'Amico TA; Harpole DH; Honeycutt W; Yu D; Bendell JC
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1002-7. PubMed ID: 17197129
[TBL] [Abstract][Full Text] [Related]
20. Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: results of a phase II trial.
Keresztes RS; Port JL; Pasmantier MW; Korst RJ; Altorki NK
J Thorac Cardiovasc Surg; 2003 Nov; 126(5):1603-8. PubMed ID: 14666040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
